Protein SSX2 (101-111)

Protein SSX2 (101-111) is a synthetic peptide segment corresponding to amino acids 101 through 111 of the Synovial Sarcoma, X Breakpoint 2 (SSX2) protein. As a member of the cancer-testis antigen family, SSX2 is notable for its restricted expression in normal adult tissues and its frequent upregulation in certain malignancies, particularly synovial sarcomas and other tumors. The 101-111 sequence is recognized as an immunologically relevant epitope, making it a valuable tool in the study of antigen processing, immune recognition, and tumor immunology. Researchers leverage this peptide to dissect the molecular mechanisms underlying SSX2 function, to explore its antigenic properties, and to facilitate the development of analytical assays for basic and translational research.

Epitope mapping: The SSX2 (101-111) peptide is widely used in epitope mapping studies to identify and characterize the specific regions of the SSX2 protein recognized by antibodies or T-cell receptors. By employing this defined peptide fragment in immunoassays, researchers can pinpoint immune-dominant determinants within the SSX2 sequence, elucidating the molecular basis of immune recognition in cancer and autoimmunity. Such mapping efforts are critical for understanding the specificity of immune responses and for guiding the design of targeted immunological reagents.

Immunological assays: In the context of immunological research, this peptide serves as a standard reagent for evaluating T-cell responses in vitro. It is frequently incorporated into enzyme-linked immunospot (ELISPOT) assays, intracellular cytokine staining, and tetramer-based flow cytometry to assess the presence and function of SSX2-specific cytotoxic T lymphocytes (CTLs) in patient-derived samples or experimental models. These applications are instrumental in monitoring immune reactivity, assessing immunogenicity, and supporting the development of antigen-specific immunotherapies.

Peptide-based vaccine research: The SSX2 (101-111) sequence is a candidate for studies aiming to develop peptide-based cancer vaccines. Its well-defined structure and immunogenic properties allow scientists to investigate strategies for eliciting targeted cytotoxic T-cell responses against SSX2-expressing tumor cells. Research in this area focuses on optimizing peptide formulations, delivery methods, and adjuvant systems to enhance immunogenicity and specificity, thereby advancing the field of tumor antigen-based vaccine design.

Analytical method development: This peptide is a valuable reference standard and calibration reagent in the development of mass spectrometry-based proteomic assays. Its defined sequence and physicochemical properties facilitate the validation of peptide identification, quantification protocols, and the benchmarking of analytical sensitivity. Utilization in this context enables accurate detection and quantitation of SSX2-derived peptides in complex biological samples, supporting biomarker discovery and proteomic profiling efforts.

Structural and functional studies: Researchers employ the SSX2 (101-111) peptide to investigate the structural determinants of protein-protein and protein-antibody interactions. By analyzing its binding characteristics, conformational preferences, and interaction profiles, scientists gain insights into the functional relevance of the SSX2 region within the broader protein context. Such studies contribute to a deeper understanding of SSX2's role in cellular processes and its potential as a molecular target in oncology and immunology research.

1. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

2. Myotropic activity of allatostatins in tenebrionid beetles

3. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

4. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

5. Cationic cell-penetrating peptides are potent furin inhibitors